People: ChemoCentryx Inc (CCXI.O)

Summary

Name	Age	Since	Current Position
Thomas Schall	53	2012	Chairman of the Board, President, Chief Executive Officer
Susan Kanaya	50	2006	Chief Financial Officer, Senior Vice President - Finance, Secretary
Juan Jaen	55	2010	Senior Vice President - Drug Discovery, Chief Scientific Officer
Petrus Bekker	52	2009	Senior Vice President - Clinical and Medical Affairs
Markus Cappel	52	2007	Chief Business Officer, Treasurer
Roger Lucas	70	2012	Lead Independent Director
Joseph Feczko	64	2012	Independent Director
Geoffrey Parker	48	2009	Independent Director
Edward Penhoet	73	2007	Independent Director
James Tyree	60	2012	Independent Director

» Insider Trading

Biographies

Name	Description
Thomas Schall	Dr. Thomas J. Schall is Chairman of the Board, President, Chief Executive Officer of ChemoCentryx, Inc. He is the founder of company and has served as President, Chief Executive Officer and Director since company commenced operations in 1997 and was appointed Chairman of the Board in April 2012. From 1993 to March 1997, Dr. Schall worked at the DNAX Research Institute, a division of Schering-Plough Corporation, a pharmaceutical company. Prior to his work at the DNAX Research Institute, he worked as a scientist with Genentech, Inc., a pharmaceutical company. Dr. Schall participated in some of the earliest discoveries of chemokine system function and activities. Dr. Schall cloned one of the first chemokines to be discovered, and provided some of the earliest data for the existence of the previously unknown of molecules which later came to be called the chemokines. Dr. Schall’s laboratories have been responsible for the discovery or co-discovery of almost one-third of all known chemokine receptors. Dr. Schall received his B.S. in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University.
Susan Kanaya	Ms. Susan M. Kanaya is Chief Financial Officer, Senior Vice President - Finance, Secretary of ChemoCentryx, Inc. She has served as Senior Vice President, Finance, and Chief Financial Officer since January 2006, and Secretary since February 2006. Prior to joining company, Ms. Kanaya served as Senior Vice President, Finance, and Chief Financial Officer at Kosan Biosciences Inc., a biotechnology company, from 1999 to 2005. Prior to this, she served in financial management positions at SUGEN, Inc., a biotechnology company, from 1994 to 1999, most recently as Vice President, Finance, and Treasurer. Ms. Kanaya served as Controller with high technology companies and as a public accountant with KPMG. Ms. Kanaya received her B.S. in business administration from the University of California, Berkeley.
Juan Jaen	Dr. Juan C. Jaen is Senior Vice President - Drug Discovery, Chief Scientific Officer of ChemoCentryx, Inc. He has served as Chief Scientific Officer since February 2010. From January 2007 to February 2010, Dr. Jaen served as Senior Vice President, Drug Discovery. From 1996 to 2006, Dr. Jaen was employed at Tularik, a biotechnology company, and then Amgen Inc., a pharmaceutical company (following Tularik’s acquisition by Amgen in 2004), most recently serving as Vice President of Chemistry. From 1983 to 1996, Dr. Jaen was employed at Parke-Davis/Warner-Lambert, a pharmaceutical company, most recently as Chemistry Director, with responsibility for the neurodegenerative disease research area. Dr. Jaen received his B.S. from the Universidad Complutense in Madrid, Spain and holds a Ph.D. in organic chemistry from the University of Michigan.
Petrus Bekker	Mr. Petrus J. Bekker is Senior Vice President - Clinical and Medical Affairs of ChemoCentryx, Inc. He has served as Senior Vice President of Clinical and Medical Affairs since February 2009. From April 2005 to February 2009, Dr. Bekker served as Vice President of Clinical and Medical Affairs. Prior to joining company, Dr. Bekker worked at Amgen Inc., where he served as Senior Director of Global Safety from July 2004 to April 2005 and as Senior Director of Clinical Development and Director of Clinical Development from December 1997 to July 2004. Prior to this, he served as a clinical researcher and scientist at Procter & Gamble Pharmaceuticals in various capacities for seven years. Dr. Bekker received his Ph.D. in molecular biology from Pennsylvania State University and his M.D. and medical training in South Africa at the University of Pretoria.
Markus Cappel	Dr. Markus J. Cappel is Chief Business Officer, Treasurer of ChemoCentryx, Inc., since February 2007. He was Treasurer since August 2004. From March 2003 to February 2007, he served as Senior Vice President of Corporate and Business Development. From October 2001 to March 2003, Dr. Cappel served as Vice President of Business Development. Prior to joining company, Dr. Cappel served as Vice President of Business Development at Alkermes, Inc., a biotechnology company, from 1998 to 2001. Prior to this, he served as Director of Business Development with Millennium Pharmaceuticals as well as in various business development roles at Cygnus, Inc., a biotechnology company. Dr. Cappel received his B.S. in pharmacy and his Ph.D. in pharmaceutics from J.W. Goethe University, Frankfurt, Germany, and his M.B.A. from Harvard Business School. Dr. Cappel completed postdoctoral studies in pharmaceutics at the University of Michigan.
Roger Lucas	Dr. Roger C. Lucas is Lead Independent Director of ChemoCentryx, Inc. He has served as a member of board of directors since September 1997 and was appointed Lead Independent Director in April 2012. Since 1995, Dr. Lucas has served as Vice Chairman and a member of the board of directors of Techne Corporation, a biotechnology company. From 1985 to 1995, Dr. Lucas served as the Chief Scientific Officer, Senior Executive Vice President and Secretary of Techne Corporation and the founder of its Biotechnology Division. Prior to this, Dr. Lucas was Vice President of Research at R&D Systems, now a subsidiary of Techne, where he worked for over 10 years. Dr. Lucas received his B.S. in biology and chemistry from St. Mary’s College, Minnesota, and his Ph.D. in physiology and cell biology from the Illinois Institute of Technology. Dr. Lucas serves on the board of directors of a number of privately held companies. .
Joseph Feczko	Dr. Joseph M. Feczko is an Independent Director of ChemoCentryx, Inc., since April 30, 2012. Until his retirement in May 2009, Dr. Feczko was Senior Vice President and Chief Medical Officer of Pfizer Inc. and a member of its Executive Leadership Team with global responsibilities for all aspects of the company’s medical, regulatory and safety activities. Dr. Feczko served Pfizer in both New York and the United Kingdom since 1982, where he held positions of increasing responsibility in clinical research and regulatory affairs and safety, culminating in the role of Chief Medical Officer. Dr. Feczko is board-certified in Internal Medicine and Infectious Diseases. He has a B.S. degree from Loyola University Chicago, and an M.D. from the University of Illinois College of Medicine. Dr. Feczko also serves on the board of directors of Keryx Biopharmaceuticals, Inc. and Cytheris, SA. Dr. Feczko also serves as chairman of the board of directors of Cardoz Pharmaceuticals AB (Stockholm, Sweden) and as a member of the Supervisory Board of uniQure B.V., based in The Netherlands.
Geoffrey Parker	Mr. Geoffrey M. Parker is an Independent Director of ChemoCentryx, Inc., since December 2009. Since September 2010, Mr. Parker has served as Senior Vice President and Chief Financial Officer of Anacor Pharmaceuticals, Inc. after serving in a consulting capacity since December 2009. From July 2009 to July 2010, Mr. Parker served in a consulting capacity as Chief Business Officer of InteKrin Therapeutics, Inc., a biotechnology company, and previously served as Managing Director and Partner in the Investment Banking Division of Goldman, Sachs & Co. From 1997 to 2009, Mr. Parker directed Goldman Sachs’ West Region Healthcare Investment Banking practice. From 1995 to 1997, Mr. Parker was Vice President at Feibusch & Co., a venture capital firm in Larkspur, California. Mr. Parker received his A.B. in Engineering Sciences and Economics from Dartmouth College and his M.B.A. from Stanford University.
Edward Penhoet	Dr. Edward E. Penhoet is an Independent Director of ChemoCentryx, Inc., since December 2007. Since August 2000, Dr. Penhoet has served as a director of Alta Partners, a venture capital firm. Dr. Penhoet is currently a member of the President’s Council of Advisors for Science and Technology (PCAST). Dr. Penhoet was a member of the Independent Citizens Oversight Committee of the California Institute of Regenerative Medicine where he served as the Vice Chairman from 2004 to 2008. From July 1998 to July 2002, Dr. Penhoet served as the Dean of the School of Public Health and as a Professor of Public Health and of Molecular and Cellular Biology at the University of California, Berkeley. Dr. Penhoet was a co-founder of the Chiron Corporation, a biotechnology company, where he served as President, Chief Executive Officer and a director from its formation in 1981 to April 1998. From 1971 to 1981, Dr. Penhoet was a faculty member of the Biochemistry Department at the University of California, Berkeley. From 2004 to 2008, Dr. Penhoet served as President of the Gordon and Betty Moore Foundation. Dr. Penhoet is a member of the Institute of Medicine of the National Academy of Sciences and The American Academy of Arts & Sciences and currently serves, or has during the past five years served, as a director of Chiron, Corcept Therapeutics, Inc., IDM Pharma, Inc. and Renovis, Inc., together with several privately held biotechnology companies. Dr. Penhoet received a B.A. in Biology from Stanford University and a Ph.D. in Biochemistry from the University of Washington.
James Tyree	Mr. James L. Tyree is an Independent Director of ChemoCentryx, Inc., since June 5, 2012. During the last fourteen years, Mr. Tyree has held numerous executive positions at Abbott Laboratories, including Corporate Vice President Pharmaceutical and Nutritional Products Group Business Development, Senior Vice President Global Nutrition and Executive Vice President Global Pharmaceuticals. He retired as President Abbott Biotechnology Ventures on March 31, 2012. Prior to joining Abbott, Mr. Tyree was the President of SUGEN, Inc., a biotechnology company focused on oncology. Earlier in his career, Mr. Tyree held management positions in Bristol-Myers Squibb, Pfizer and Abbott. Over his entire career, he was a four-time expatriate living and working over six years in Latin America and seven years in Japan. Mr. Tyree is a member of the Advisory Board of the University of Chicago Booth Graduate School of Business, a member of the Chicago Council on Global Affairs and co-chairman of the Global Health Policy Roundtable. Mr. Tyree also serves as a director for a number of privately held companies. Mr. Tyree earned Bachelor's Degrees in Psychology and Forensic Studies and a Master's Degree in Business Administration from Indiana University.

Basic Compensation

Name	Fiscal Year Total
Thomas Schall	6,450,660
Susan Kanaya	1,762,600
Juan Jaen	683,735
Petrus Bekker	309,429
Markus Cappel	1,774,220
Roger Lucas	--
Joseph Feczko	--
Geoffrey Parker	--
Edward Penhoet	--
James Tyree	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
Thomas Schall	0	0
Susan Kanaya	0	0
Juan Jaen	0	0
Petrus Bekker	57,000	74,100
Markus Cappel	0	0
Roger Lucas	0	0
Joseph Feczko	0	0
Geoffrey Parker	0	0
Edward Penhoet	0	0
James Tyree	0	0

Insider Trading

Name	Shares Traded	Price
BEKKER PETRUS	5,000	$13.59
CAPPEL MARKUS J	5,852	$13.90
SCHALL THOMAS J	7,600	$14.04
KANAYA SUSAN M	799	$2.00
CAPPEL MARKUS J	5,852	$0.60
CAPPEL MARKUS J	3,566	$14.13
CAPPEL MARKUS J	6,250	$14.23
BEKKER PETRUS	10,000	$14.16
KANAYA SUSAN M	799	$14.38
LUCAS ROGER C	5,000	$14.11
SCHALL THOMAS J	2,312	$14.02
BEKKER PETRUS	3,979	$6.00
CAPPEL MARKUS J	1,500	$0.60
CAPPEL MARKUS J	1,500	$14.10
BEKKER PETRUS	3,979	$14.03
SCHALL THOMAS J	217	$14.00
LUCAS ROGER C	5,000	$13.49
CAPPEL MARKUS J	6,250	$13.47
BEKKER PETRUS	64	$14.00
SCHALL THOMAS J	200	$14.00
BEKKER PETRUS	64	$6.00
BEKKER PETRUS	957	$6.00
BEKKER PETRUS	957	$14.00
SCHALL THOMAS J	556	$14.00
CAPPEL MARKUS J	1,783	$13.51

» Full list on Insider Trading

People: ChemoCentryx Inc (CCXI.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: